A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities

Trial Profile

A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Febuxostat (Primary) ; Allopurinol
  • Indications Gout
  • Focus Adverse reactions; Registrational
  • Acronyms CARES
  • Sponsors Takeda
  • Most Recent Events

    • 12 Mar 2018 According to the Takeda media release, company has submitted study results to the FDA as a post-marketing requirement and FDA is working with the agency to conduct a comprehensive review of the data.
    • 12 Mar 2018 According to the Takeda media release, results from this trial were published the New England Journal of Medicine (NEJM) and presented at the American College of Cardiology's (ACC) 67th Annual Scientific Session & Expo.
    • 12 Mar 2018 Results presented in the Takeda media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top